Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia by Jimenez Naranjo, Carlos et al.
University of Wollongong
Research Online
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health
2019
Effect of cannabidiol on muscarinic
neurotransmission in the pre-frontal cortex and





University of Wollongong, alo649@uowmail.edu.au
Katrina Weston-Green
University of Wollongong, Australian Centre for Cannabinoid Clinical and Research Excellence, kweston@uow.edu.au
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Jimenez Naranjo, C., Osborne, A. L. & Weston-Green, K. (2019). Effect of cannabidiol on muscarinic neurotransmission in the pre-
frontal cortex and hippocampus of the poly I:C rat model of schizophrenia. Progress in Neuropsychopharmacology and Biological
Psychiatry, 94 109640-1-109640-11.
Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal
cortex and hippocampus of the poly I:C rat model of schizophrenia
Abstract
Cognitive impairment is a core symptom of schizophrenia; however, current antipsychotic drugs have limited
efficacy to treat these symptoms and can cause serious side-effects, highlighting a need for novel therapeutics.
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid that has demonstrated pro-cognitive effects in
multiple disease states, including a maternal immune activation (poly I:C) model of schizophrenia, but the
mechanisms underlying the efficacy of CBD require investigation. Muscarinic neurotransmission is highly
implicated in the cognitive impairments of schizophrenia; however, the effect of CBD on this system is
unknown. We examined alterations in markers of muscarinic neurotransmission in the pre-frontal cortex
(PFC) and hippocampus (HPC) following CBD treatment. Pregnant Sprague-Dawley rats (n=16) were
administered poly I:C (4 mg/kg) or saline. Adult offspring were treated (3-weeks) with CBD (10 mg/kg) or
vehicle. Receptor autoradiography (using [3H]pirenzepine) was used to examine changes in muscarinic M1/
M4 receptor (M1/M4R) binding density. Levels of choline acetyltransferase (ChAT) and
acetylcholinesterase (AChE) protein expression were examined using Western blot. M1/M4R binding
density was downregulated in the PFC and CA1/CA2 and CA3 subregions in male poly I:C offspring. M1/
M4R deficits were normalised after CBD treatment. ChAT protein expression was reduced in the HPC of
male poly I:C offspring, while CBD treated poly I:C offspring exhibited control-like ChAT levels. AChE levels
were unaltered in any of the groups. There were also no changes in muscarinic signalling in female offspring.
These findings demonstrate that CBD can normalise muscarinic neurotransmission imbalances in male poly
I:C offspring in regions of the brain implicated in cognition.
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Cognitive impairment is a core symptom of schizophrenia; however, current antipsychotic 27 
drugs have limited efficacy to treat these symptoms and can cause serious side-effects, 28 
highlighting a need for novel therapeutics. Cannabidiol (CBD) is a non-intoxicating 29 
phytocannabinoid that has demonstrated pro-cognitive effects in multiple disease states, 30 
including a maternal immune activation (poly I:C) model of schizophrenia, but the mechanisms 31 
underlying the efficacy of CBD require investigation. Muscarinic neurotransmission is highly 32 
implicated in the cognitive impairments of schizophrenia; however, the effect of CBD on this 33 
system is unknown. We examined alterations in markers of muscarinic neurotransmission in 34 
the pre-frontal cortex (PFC) and hippocampus (HPC) following CBD treatment. Pregnant 35 
Sprague-Dawley rats (n =16) were administered poly I:C (4 mg/kg) or saline. Adult offspring 36 
were treated (3-weeks) with CBD (10 mg/kg) or vehicle. Receptor autoradiography (using 37 
[3H]pirenzepine) was used to examine changes in muscarinic M1/M4 receptor (M1/M4R) 38 
binding density. Levels of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) 39 
protein expression were examined using Western blot. M1/M4R binding density was 40 
downregulated in the PFC and CA1/CA2 and CA3 subregions in male poly I:C offspring. 41 
M1/M4R deficits were normalised after CBD treatment. ChAT protein expression was reduced 42 
in the HPC of male poly I:C offspring, while CBD treated poly I:C offspring exhibited control-43 
like ChAT levels. AChE levels were unaltered in any of the groups. There were also no changes 44 
in muscarinic signalling in female offspring. These findings demonstrate that CBD can 45 
normalise muscarinic neurotransmission imbalances in male poly I:C offspring in regions of 46 
the brain implicated in cognition.  47 
 48 
Keywords: cannabidiol; muscarinic; acetylcholine; maternal immune activation; 49 
schizophrenia; cognition. 50 
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1. INTRODUCTION 51 
Cognitive impairment is experienced by 75-85% of patients with schizophrenia (Barch and 52 
Ceaser, 2012) and has been recognised as a core symptom domain from which the other 53 
symptoms may arise [1]. It often precedes the onset of psychotic symptoms, is evident in first 54 
episode psychosis [2] and can be a predictor of functional outcomes [3]. Current antipsychotic 55 
drugs (APDs) are limited in their ability to treat cognitive symptoms in schizophrenia and 56 
recent data suggests that high lifetime APD dosing potentiates cognitive deficits [4]. APDs can 57 
also cause negative side effects such as obesity and type 2 diabetes mellitus [5]. Therefore, 58 
there is a need to improve APD therapy to target cognitive dysfunction while avoiding adverse 59 
side effects.  60 
Cannabidiol (CBD) is a major phytocannabinoid of Cannabis sativa L., produced as a 61 
metabolic by-product of the plant through decarboxylation of cannabidiolic acid [6]. It is 62 
psychoactive, i.e. alters brain function to affect behaviour [7], but there is currently no evidence 63 
that it causes the deleterious hallucinogenic, paranoia and anxiety-inducing effects that can 64 
occur with misuse of the delta-tetrahydrocannabinol (Δ-THC) type chemicals [8]. CBD has 65 
pro-cognitive effects in multiple disease states of cognitive impairment [see 9, 10 for review]. 66 
In addition, clinical studies have reported improved positive and negative symptoms in people 67 
with schizophrenia following CBD administration [11], with similar therapeutic efficacy to the 68 
APD amisulpride, a high tolerability and low negative side effects [12]. A limited number of 69 
clinical studies examined cognition in schizophrenia using CBD as an adjunct therapy to 70 
existing APDs showed only modest, if any, improvement in cognitive performance in patients 71 
with chronic stable schizophrenia [11, 13]. The effect of chronic CBD treatment alone on 72 
cognition in schizophrenia patients requires examination. We recently reported that chronic (3-73 
weeks) CBD enhanced cognition and sociability in a maternal immune activation (MIA) rat 74 
model of schizophrenia [7]. In this model, administration of polyinosinic-polycytidilic acid (poly 75 
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I:C, a synthetic double-stranded RNA viral mimic) to pregnant rats during mid-late gestation 76 
increases pro-inflammatory cytokines that cross the placenta causing inflammation of the foetal 77 
brain and altering the neurodevelopmental trajectory of the offspring [14]. Poly I:C offspring 78 
display numerous behavioural, neurochemical and structural brain abnormalities observed in 79 
schizophrenia patients [14-16]. In particular, we found that male poly I:C offspring had deficits 80 
in recognition and working memory (assessed using the Novel Object Recognition (NOR) and 81 
T Maze tests, respectively), as well as reduced social interaction during the Social Interaction 82 
test, while CBD treated these deficits [7]. In female offspring, the poly I:C group exhibited 83 
deficits in recognition memory and social interaction that were treated using CBD, while 84 
female poly IC offspring did not exhibit impaired working memory [17]. However, the 85 
mechanisms by which CBD treats cognitive deficits in the poly I:C model are unknown. 86 
The cholinergic system is composed of two major families of receptors: acetylcholine nicotinic 87 
and muscarinic receptors (mAChRs). Mice deficient in the muscarinic M1 receptor (M1R) 88 
subtype exhibit impairments in working memory and remote reference memory [18].  In 89 
addition, significant reductions in the expression of M1R and muscarinic M4 receptors (M4R) 90 
have been reported in post-mortem brains of schizophrenia patients in regions related to 91 
cognitive function, including the hippocampus and frontal cortex [reviewed in 19]. It has also 92 
been demonstrated that the expression of M1R protein, but not other mAChR subtypes, is 93 
decreased in the dorsolateral prefrontal cortex of people with schizophrenia [20]. Altogether, 94 
these findings suggest that alterations in the M1R may play a role in the cognitive dysfunction 95 
of schizophrenia. In cholinergic neurons, two main enzymes are essential to acetylcholine 96 
(ACh) neurotransmission: choline acetyltransferase (ChAT) for ACh synthesis in the pre-97 
synaptic neuron, and acetylcholinesterase (AChE), which is located in the post-synaptic neuron 98 
and degrades ACh in the synaptic cleft following its release [21]. In previous studies, decreased 99 
activity of ChAT has been correlated with poor cognitive functioning in schizophrenia patients 100 
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[22], while AChE inhibitors have been shown to slow the cognitive decline in Alzheimer’s 101 
disease [23], demonstrating that ChAT and AChE activity impact cognitive functioning. 102 
Interestingly, acute CBD increases ACh in the basal forebrain within hours of systemic 103 
administration [24], unlike cannabinoid CB1 receptor (CB1R) agonists (Δ9-104 
tetrahydrocannabinol, WIN 55,212-2 and CP 55,940 administered systemically) that inhibit 105 
ACh release in the rat pre-frontal cortex and hippocampus [25, 26]. Therefore, there is evidence 106 
of a link between CBD, the cholinergic muscarinic neurotransmission system, schizophrenia 107 
and cognitive function. The aim of this study was to examine the effect of CBD treatment on 108 
muscarinic neurotransmission (M1/M4R density, ChAT and AChE protein levels) in regions 109 
of the brain implicated in learning, memory and schizophrenia pathology in poly I:C offspring.  110 
 111 
2. METHODS 112 
 113 
2.1 Ethics Statement 114 
Experimental procedures were approved by the Animal Ethics Committee of the University of 115 
Wollongong, Wollongong, NSW, Australia (AE15/05) and complied with the Australian Code 116 
of Practice for the Care and Use of Animals for Scientific Purposes (National Health and 117 
Medical Research Council [27]. All efforts were made to minimise suffering and the number 118 
of animals used.  119 
 120 
2.2 Animals and Treatment 121 
The methods relating to the animal housing and treatment were previously reported by our 122 
laboratory [7] and in accordance with the Animal Research: Reporting of In Vivo Experiments 123 
(ARRIVE) guidelines [28]. Briefly, sixteen pregnant Sprague-Dawley rats (Animal Resource 124 
Centre, Perth, WA, Australia) received an intravenous injection of either poly I:C (4mg/kg, 125 
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Sigma-Aldrich, Sydney, NSW, Australia; n = 8) or saline solution (control; n = 8) at gestation 126 
day 15. Dose and timing of poly I:C administration was based on previous studies [15]. Male 127 
and female offspring received twice-daily intraperitoneal (i.p) injections of CBD (10 mg/kg; 128 
THC-Pharm GmbH, Frankfurt, Germany) dissolved in Tween 80 and saline (vehicle; 1:16 129 
(v/v); Sigma-Aldrich), or vehicle alone (injection volume of 5ml/kg) (n = 12 per group). 130 
Treatment began on postnatal day 56, which equates to late adolescence/early adulthood in 131 
humans [29]. After 2-weeks of treatment, rats were submitted to a series of behavioural tests, 132 
including the Novel object recognition (NOR) test, Rewarded T-maze alternation test and the 133 
Social interaction test to assess the effects of CBD on recognition memory, working memory 134 
and sociability, respectively [7, 17]. The behavioural data were published elsewhere [7, 17]. In 135 
order to examine the mechanisms by which CBD treated the cognitive deficits in poly I:C 136 
offspring, the brain tissue from our previous studies [7, 17] was analysed in the present study.  137 
 138 
2.3 Histological Procedures 139 
After 3 weeks of treatment, animals were euthanized via carbon dioxide asphyxiation followed 140 
by rapid decapitation, approximately 10-12 hours after the last drug treatment. Brains were 141 
removed, immediately frozen in liquid nitrogen and stored at -80ºC until processing. Rat brains 142 
(n = 8 per group) were sectioned coronally into alternating 14 µM or 500 µM thick sections 143 
using a cryostat (Jung CM 3000, Leica Instruments GmbH, Nussloch, Germany). Sections 144 
included the prefrontal cortex (PFC, ie prelimbic and infralimbic cortices) and hippocampus 145 
(HPC, ie CA1/2 and CA3 subregions) (Bregma: 4.2 to 2.56 mm and -4.36 to -6.00mm, 146 
respectively) using a standard rat brain atlas [30] (Figure 1). Sections collected for receptor 147 
autoradiography experiments (14 µM) were thaw-mounted on to PolysineTM slides (Sigma-148 
Aldrich, Castle Hill, NSW Australia) and stored at -20ºC until further analysis. Sections 149 
collected for Western blot experiments (500 µM) were mounted on glass slides, microdissected 150 
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using a micropuncture kit and stored at -80ºC. The dissection methods enabled examination of 151 
receptor binding and protein expression from the same rat brain. 152 
 153 
2.4 Receptor Autoradiography 154 
 155 
2.4.1 M1/M4R binding  156 
The methods used to detect M1/M4R binding density were conducted as previously described 157 
by our laboratory [31]. Briefly, slides containing two consecutive sections, per region for each 158 
rat, were air-dried and pre-incubated in 22 mM HEPES buffer (pH 7.5) for 15 min at room 159 
temperature. To examine total binding, sections were incubated in HEPES buffer containing 160 
10 nM [3H]pirenzepine (72.8 Ci/mmol; PerkinElmer TM Life and Analytical Sciences, Boston, 161 
USA) for 90 min at room temperature. Non-specific binding was determined by incubating an 162 
additional two consecutive sections in 10 nM [3H]pirenzepine in the presence of atropine (10 163 
μM), a competitive antagonist of muscarinic receptors, in buffer (pH 7.5) for 90 min at room 164 
temperature. After incubation, sections were washed three times for 4 min in ice-cold HEPES 165 
buffer, then dipped in ice cold milliQ water and air-dried overnight. 166 
 167 
2.4.2 Quantification 168 
Slides were exposed to Amersham Hyperfilm ECL (GE Healthcare Life Sciences, Parramatta, 169 
NSW, Australia) for 7 weeks in X-ray film cassettes with a set of tritium standards (Amersham, 170 
Buckinghamshire, United Kingdom). Autoradiographs were developed using standard 171 
procedures, scanned using a GS-800 Imaging Densitometer (Bio-Rad, Hercules, California, 172 
USA) and analysed with Image J software (https://imagej.nih.gov/ij). Images were calibrated 173 
based on the Rodbard curve obtained from the tritium standards to produce nCi/mg tissue 174 
equivalent (TE) values. Regions of interest included the PFC and the CA1/2 and CA3 regions 175 
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of the HPC. Specific binding densities were calculated by subtracting non-specific binding 176 
from total binding values. Values were converted to fmoles [3H] ligand per mg TE, taking into 177 
account the specific activity of the ligand, as we have described previously [32-34]. Anatomical 178 
structures of interest were confirmed using a standard rat brain atlas [30].  179 
 180 
2.5 Western Blot 181 
Microdissected brain tissue samples (PFC, HPC with the CA1/2 and CA3 subregions 182 
combined) were homogenised in homogenising buffer (0.1 M Tris-HCl, 2 mM EDTA, 10% 183 
glycerol, 2% SDS, 0.5 mM PMSF, Protease Inhibitor Cocktail (P8340; Sigma-Aldrich, Castle 184 
Hill, NSW, Australia) and Phosphatase Inhibitor Cocktail 2 (P5726; Sigma-Aldrich, Castle 185 
Hill, NSW, Australia)). Total protein concentration was determined using a DC Protein Assay 186 
kit (Bio-Rad, Gladesville, NSW, Australia). Proteins were loaded in equal amounts (10 ug, 187 
within the linear range for each antibody target) into TGXTM 4-20% Stain-free Precast Gels 188 
(Bio-Rad, Australia) to undergo SDS-PAGE electrophoresis at 180V for 1 hr. Stain-free gels 189 
were activated (GelDoc XR+ imaging system; Bio-Rad, Australia) [35, 36], proteins were 190 
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Gladesville, NSW 191 
Australia) at 100V for 1 hr, and imaged to capture total protein in each lane [35, 36]. PVDF 192 
membranes were washed in Tris Buffered Saline with Tween 20 (TBST) (3 x 5 min) and 193 
blocked in non-fat milk for 1 hr at room temperature. Membranes were then incubated 194 
overnight in anti-ChAT (1:10000, #ab181023, Abcam, Melbourne, VIC, Australia) or anti-195 
AChE (1:5000, #ab183591, Abcam, Melbourne, VIC, Australia) primary antibodies. 196 
Membranes were washed in TBST (5 x 5 min) and incubated in goat anti-rabbit secondary 197 
antibody (1:5000, #AB307P, Merck Millipore, Bayswater, VIC, Australia) for 60 min at room 198 
temperature. Membranes were washed in TBST (3 x 5 min), incubated in ECL reagent (GE 199 
Healthcare, Parramatta, NSW, Australia) and exposed to a Gel Imager (600RB, Amersham, 200 
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GE Healthcare, Parramatta, NSW, Australia). Band density was quantified using Image Lab 201 
software (ver 6, Bio-Rad Laboratories Inc, California, USA). Samples were examined in 202 
duplicate. The values for each signal were normalised to total protein in the respective lane to 203 
account for loading variability. Values were then normalised to an internal control (pooled 204 
sample) on each gel, to account for gel-to-gel variability and allow comparison of samples 205 
across gels. 206 
 207 
2.6 Statistical Analysis 208 
Data were analysed using SPSS (Version 21.0, IBM, Chicago, Illinois, USA). All data points 209 
included in analyses were within ±2SD of the mean. Shapiro-Wilk tests were used to test data 210 
for normality. A two-way Analysis of Variance (ANOVA) was used to test for an effect of 211 
PRENATAL INFECTION (POLY vs CONT) and OFFSPRING TREATMENT (CBD vs 212 
VEH) on receptor binding density and protein expression in the PFC and HPC. Where 213 
significant interactions were observed, pairwise comparisons (with Bonferonni’s adjustment) 214 
were made between groups. Male and female data were analysed separately due to sexual 215 
dimorphism in neuropsychiatric trajectory observed in the model [37] and the endocannabinoid 216 
system in rats [38]. Comparisons between vehicle-treated control and poly I:C offspring 217 
(CONT+VEH vs. POLY+VEH), vehicle and CBD-treated poly I:C offspring (POLY+VEH vs. 218 
POLY+CBD), as well as vehicle and CBD-treated control offspring (CONT+VEH vs. 219 
CONT+CBD) were examined. Where applicable, comparisons between CBD-treated poly I:C 220 
offspring and vehicle-treated control offspring (POLY+CBD vs. CONT+VEH) were 221 
conducted using independent T tests to examine whether CBD treatment restored control-like 222 
levels in poly I:C offspring. Correlations between binding density, protein expression and 223 
behavioural parameters were examined using Pearson’s correlation tests for parametric data. 224 
Statistical significance was set at p < 0.05 and p values between 0.05 and 0.1 were considered 225 
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statistical trends. Data were presented as mean  standard error of the mean (SEM). 226 
 227 
3. RESULTS 228 
We previously reported that male poly I:C offspring exhibit significantly reduced working 229 
memory (decreased percentage of correct entries in the T Maze), recognition memory (decreased 230 
Discrimination Ratio in the Novel Object Recognition Test) and social interaction (decreased 231 
Total Interaction Time in the Social Interaction test) compared to controls, whereas CBD treated 232 
these deficits [7]. We have also previously shown that the female poly I:C offspring had 233 
reductions in the Discrimination Ratio and Total Interaction Time that were treated using CBD, 234 
but unlike males, working memory performance in the T Maze test was not altered by poly I:C 235 
or CBD [17]. In the present study, we examined alterations to markers of cholinergic muscarinic 236 
neurotransmission in the PFC and HPC of the brain tissue from those rodents. 237 
 238 
3.1 M1/M4R Binding Density in the PFC and HPC of offspring 239 
Examples of [3H]Pirenzepine binding to M1/M4Rs are presented in Figure 1, with M1/M4R 240 
binding observed across the PFC, and CA1/CA2 and CA3 regions of the HPC. There were no 241 
significant main effects of PRENATAL INFECTION (F (1, 19) = 2.91, p = 0.10) or OFFSPRING 242 
TREATMENT (F (1, 19) = 1.40, p = 0.25) on M1/M4R binding density in the PFC of male 243 
offspring, but a significant interaction between the factors was observed (F (1, 19) = 5.34, p = 244 
0.03). M1/M4R binding density was reduced in male poly I:C offspring compared to controls 245 
(-16.3%; POLY+VEH vs. CONT+VEH, p = 0.01) (Figure 2A); however, CBD treatment 246 
restored M1/M4R binding density levels in male poly I:C offspring that were no longer 247 
different to controls (POLY+CBD vs CONT+VEH, p = 0.18) (Figure 2A). In addition, CBD 248 
significantly reduced M1/M4R binding density in control offspring (-14.2%, CONT+CBD vs. 249 




Figure 1: Example autoradiographs to demonstrate [3H]Pirenzepine binding to M1/M4Rs in 252 
the offspring brain. Schematic diagrams (left panel) showing the approximate Bregma levels 253 
examined in the prefrontal cortex (PFC; 2.52 mm), which included the prelimbic and 254 
infralimbic cortices (shaded), and the hippocampus (HPC; -4.92 mm), which included the 255 
CA1/2 and CA3 regions. Example autoradiographs show total (row 1 and 3) and non-specific 256 
(row 2 and 4) binding in the PFC and HPC, respectively, in vehicle-treated male and female 257 
offspring from control dams. Schematic diagram modified from a standard rat atlas (Paxinos 258 
and Watson (2007). The Rat Brain in Stereotaxic Coordinates. 6th Ed. Elselvier Academic Press 259 




Figure 2: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on M1/M4R 262 
([3H]Pirenzepine) binding density in the prefrontal cortex of (A) male and (B) female control 263 
(CONT) and poly I:C (POLY) offspring. Data expressed as mean ± SEM. n = 5-7 rats per 264 
group. *p<0.05 vs. CONT+VEH. TE = tissue equivalent. 265 
 266 
Conversely, there was no significant main effect of PRENATAL INFECTION (F (1, 19) = 1.17, 267 
p = 0.29) or OFFSPRING TREATMENT (F (1, 19) = 1.63, p = 0.22) on M1/M4R binding density 268 
in the PFC of female offspring, and no interaction between the factors (F (1, 19) = 1.57, p = 0.23) 269 





















































































In the HPC, there was a significant PRENATAL INFECTION x OFFSPRING TREATMENT 272 
interaction (F (1, 18) = 8.67, p = 0.01) on M1/M4R binding density in male offspring. Pairwise 273 
comparisons revealed that maternal poly I:C exposure significantly reduced M1/M4R binding 274 
density in male offspring compared to controls (-25.93%; POLY+VEH vs. CONT+VEH, p = 275 
0.009), but CBD-treated male offspring did not significantly differ to controls (POLY+CBD 276 
vs. CONT+VEH, p = 0.51) (Figure 3A). Similar to findings in the PFC, CBD administration 277 
significantly reduced M1/M4R binding density in the HPC of male control offspring (-22.59%; 278 
CONT+CBD vs. CONT+VEH, p = 0.015) (Figure 3A).  279 
 280 
Given their functionally distinct roles in memory encoding and retrieval, further analysis was 281 
performed on the CA1/2 and CA3 subregions of the HPC. There was a significant interaction 282 
between the two factors (F (1, 18) = 8.41, p = 0.01) for M1/M4R binding density in the 283 
hippocampal CA1/CA2 subregions of adult male offspring. Reflecting the changes observed 284 
in the initial HPC analysis, maternal poly I:C exposure reduced M1/M4R binding density            285 
(-24.5%, POLY+VEH vs CONT+VEH, p = 0.01), but CBD-treated rats did not differ to 286 
controls (Figure 3B) (POLY+CBD vs. CONT+VEH, p = 0.79). CBD administration 287 
significantly decreased M1/M4R binding density in control offspring (-22.1%, CONT+CBD 288 
vs CONT+VEH, p = 0.02) (Figure 3B). In the hippocampal CA3 subregion, there were also no 289 
significant main effects of PRENATAL INFECTION (F (1, 17) = 1.09, p = 0.31) or OFFSPRING 290 
TREATMENT (F (1, 17) = 0.12, p = 0.73), though a significant interaction between the two 291 
factors was observed (F (1, 17) = 5.09, p = 0.04). Further analysis showed a significant reduction 292 
in M1/M4R binding density in the male poly I:C offspring compared to the controls (-23.3%, 293 
POLY+VEH vs CONT+VEH, p = 0.04) and a non-significant trend toward a decrease in 294 
M1/M4R binding density in the male control offspring administered CBD treatment (-18.4%, 295 
CONT+CBD vs CONT+VEH, p = 0.09) (Figure 3C). CBD treatment restored control-like 296 
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levels of M1/M4R binding density in the CA3 region of poly I:C male offspring (POLY+CBD 297 
vs CONT+VEH groups (p = 0.43) (Figure 3C).   298 
 299 
Conversely, maternal poly I:C exposure and CBD treatment did not affect M1/M4R binding in 300 
the HPC of adult female offspring (Figure 3D) (PRENATAL INFECTION: F (1, 15) = 0.11, p = 301 
0.75; OFFSPRING TREATMENT: F (1, 15) = 0.38, p = 0.55; PRENATAL INFECTION x 302 
OFFSPRING TREATMENT: F (1, 15) = 0.26, p = 0.62). The same pattern was also observed 303 
when further analysis was conducted on the CA1/2 (Figure 3E) and CA3 (Figure 3F) 304 
subregions in adult female offspring (CA1/2: [PRENATAL INFECTION: F (1, 15) = 0.01, p = 305 
0.92; OFFSPRING TREATMENT: F (1, 15) = 0.22, p = 0.65; PRENATAL INFECTION x 306 
OFFSPRING TREATMENT: F (1, 15) = 0.12, p = 0.73], CA3: [PRENATAL INFECTION: F (1, 307 
14) = 0.36, p = 0.56; OFFSPRING TREATMENT: F (1, 15) = 0.34, p = 0.57; PRENATAL 308 
INFECTION x OFFSPRING TREATMENT: F (1, 15) = 0.24, p = 0.63]). 309 
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Figure 3: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on M1/M4R 310 
([3H]Pirenzepine) binding density in the hippocampus (HPC), and CA1/2 and CA3 subregions 311 
in (A-C) male and (D-F) female control (CONT) and poly I:C (POLY) offspring. Data 312 
expressed as mean ± SEM. n = 4-6 rats per group, except female CONT+CBD group where 313 
















































































































































































































































































3.2 ChAT Protein Expression in the PFC and HPC of Offspring 315 
In the PFC, there were no significant main effects of PRENATAL INFECTION (F (1, 28) = 2.55, 316 
p = 0.12) or OFFSPRING TREATMENT (F (1, 28) = 0.50, p = 0.83) and no significant 317 
interaction between these factors (F (1, 28) = 0.13, p = 0.72) in male offspring (Figure 4A). 318 
Similarly in adult female offspring, no significant effects or interactions were observed on 319 
ChAT protein levels in the PFC (Figure 4B) (PRENATAL INFECTION: F (1, 27) = 2.30, p = 320 
0.14; OFFSPRING TREATMENT: F (1, 27) = 1.04, p = 0.32; PRENATAL INFECTION x 321 
OFFSPRING TREATMENT: F (1, 27) = 1.22, p = 0.28).  322 
   323 
On the other hand, there was a significant main effect of PRENATAL INFECTION (F (1, 27) = 324 
5.154, p = 0.03) in the male HPC (CA1/2 and CA3 regions combined). Further analysis 325 
revealed a small yet significant decrease in ChAT protein expression in the HPC of male poly 326 
I:C offspring compared to the controls (-10.1%, POLY+VEH vs CONT+VEH, p = 0.02) 327 
(Figure 4C). However, there was no significant effect of OFFSPRING TREATMENT on 328 
ChAT protein expression in the HPC (F (1, 27) = 0.29, p = 0.60) and no interaction between 329 
PRENATAL INFECTION and OFFSPRING TREATMENT (F (1, 27) = 1.36, p = 0.25) in the 330 
male HPC. Hippocampal ChAT protein levels were unaltered in female offspring 331 
(PRENATAL INFECTION: F (1, 28) = 1.74, p = 0.20; OFFSPRING TREATMENT: F (1, 28) = 332 
0.05, p = 0.82; PRENATAL INFECTION x OFFSPRING TREATMENT: F (1, 28) < 0.001, p = 333 





Figure 4: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on choline 337 
acetyltransferase (ChAT) protein levels in the (A, B) prefrontal cortex (PFC) and (C, D) 338 
hippocampus (HPC) in male and female control (CONT) and poly I:C (POLY) offspring. 339 
Representative immunoblots for ChAT are shown underneath each graph. Signal intensity was 340 
normalised to total protein levels in the respective lane and an internal control sample. *p<0.05 341 
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3.3 AChE Protein Expression in the PFC and HPC of Offspring  343 
There was no significant main effect of PRENATAL INFECTION (F (1, 27) = 0.09, p = 0.76), 344 
or OFFSPRING TREATMENT (F (1, 27) = 0.66, p = 0.42) on AChE protein expression in the 345 
male PFC and no interaction between the two factors (F (1, 27) = 0.31, p = 0.59) (Figure 5A). A 346 
similar pattern was also observed in the PFC of female offspring (Figure 5B) (PRENATAL 347 
INFECTION: F (1, 28) = 0.13, p = 0.72; OFFSPRING TREATMENT: F (1, 28) = 1.65, p = 0.21; 348 
PRENATAL INFECTION x OFFSPRING TREATMENT: F (1, 28) = 0.13, p = 0.72). 349 
 350 
Similar results were identified in the HPC, with no significant effects or interactions observed 351 
in male (Figure 5C) (PRENATAL INFECTION: F (1, 28) = 0.56, p = 0.46; OFFSPRING 352 
TREATMENT: F (1, 28) = 0.71, p = 0.41; PRENATAL INFECTION x OFFSPRING 353 
TREATMENT: F (1, 28) = 0.58, p = 0.46) or female offspring (Figure 5D) (PRENATAL 354 
INFECTION: F (1, 28) = 0.09, p = 0.76; OFFSPRING TREATMENT: F (1, 28) = <0.001, p = 355 












Figure 5: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on acetylcholinesterase 366 
(AChE) protein levels in the (A, B) prefrontal cortex (PFC) and (C, D) hippocampus (HPC) in 367 
male and female control (CONT) and poly I:C (POLY) offspring. Representative immunoblots 368 
for AChE are shown underneath each graph. Signal intensity was normalised to total protein 369 
levels in the respective lane and an internal control sample. Data expressed as mean ± SEM. (n 370 
































































































































3.4 Correlations 373 
Correlations were performed to assess the relationship between markers of muscarinic 374 
neurotransmission in male and female offspring. In the PFC, protein levels of ChAT and AChE 375 
were positively correlated in female (r = 0.57, p = 0.001) (Figure 6A) and male offspring (r = 376 
0.45, p = 0.011) (Figure 6B). There was also a positive association between AChE protein 377 
levels and M1/M4R binding density levels in the HPC of female offspring (r = 0.64, p = 0.003) 378 
(Figure 6C), but this relationship was not apparent in males (r = -0.10, p = 0.67) (Figure 6D). 379 
We also examined correlations between markers of the muscarinic system in the HPC and PFC 380 
of male and female offspring and their previously reported cognitive behaviour [7, 17]. 381 
Performance in the T-maze test (percentage of correct entries) was positively correlated with 382 
M1/M4R binding density levels (r = 0.474, p = 0.04) (Figure 6E) and AChE protein levels (r = 383 
0.503, p = 0.004) (Figure 6F) in the HPC of female offspring that showed comparable working 384 
memory across treatment groups. Conversely, in male offspring that did show treatment group 385 
differences in working memory performance, these correlations were not significant 386 
(M1/M4R: r = 0.15, p = 0.52; AChE: (r = 0.04, p = 0.83). Instead, T-maze performance of male 387 
offspring was positively correlated to hippocampal ChAT protein levels (r = 0.41, p = 0.03) 388 
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Figure 6: Correlations between 
muscarinic cholinergic markers 
in the (A, B) prefrontal cortex 
(PFC) and (C, D) hippocampus 
(HPC), and with performance in 
the T-maze test (percentage of 
correct entries) (E, F, G) in male 
and female offspring. 
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4. DISCUSSION 426 
The mechanisms underlying the pro-cognitive efficacy of CBD are largely unknown. We 427 
investigated the effect of chronic CBD treatment on muscarinic neurotransmission in regions 428 
of the brain implicated in cognitive function in the poly I:C model. These experiments revealed 429 
a downregulation of M1/M4R binding density in the PFC and hippocampal CA1/CA2 and CA3 430 
subregions in male poly I:C offspring that were not present in the brains of poly I:C offspring 431 
treated with CBD. Levels of ChAT protein expression were also reduced in the HPC of male 432 
poly I:C offspring compared to healthy controls, whereas CBD-treated poly I:C offspring had 433 
control-like ChAT levels, while AChE remained unaltered in any of the groups. CBD 434 
administration to healthy male control offspring reduced M1/M4R binding density in the PFC 435 
and hippocampal subregions examined. Muscarinic neurotransmitter signalling parameters 436 
were unaltered in the PFC or HPC and its subregions of female offspring.  437 
 438 
Our finding of an M1/M4R downregulation in the PFC and HPC of male poly I:C offspring 439 
compared to offspring born to control dams is consistent with numerous post-mortem studies 440 
that have reported decreased levels of M1/M4R binding density in the schizophrenia brain, 441 
including the PFC [39-41], anterior and posterior cingulate cortices [42, 43], superior temporal 442 
gyrus [44], HPC [39, 45, 46] and caudate-putamen [47]. This result suggests that the poly I:C 443 
model mimics muscarinic dysfunction in a manner that is relevant to human schizophrenia; 444 
however, we also found that M1/M4R binding density was unaltered in the brains of female 445 
offspring. The existence of sex differences in the M1/M4R in the human schizophrenia brain 446 
is unclear. Reduced [3H]pirenzepine binding to M1/M4R in the HPC and PFC has been 447 
reported in the post-mortem schizophrenia brain in studies using predominantly (70-80%) male 448 
tissue cohorts [39, 40]; however, decreased M1/M4R binding density has also been reported in 449 
the anterior cingulate cortex of a predominantly female schizophrenia cohort [42]. A possible 450 
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explanation for the difference between male and female M1/M4R binding density results is the 451 
potential influence of the estrous cycle, as ACh levels fluctuate depending on the stage of the 452 
cycle [48]. The estrous cycle was not measured in the present study and should be considered 453 
for future studies examining cholinergic systems in female rodents; however, the low data 454 
variability in our study suggests that the estrous cycle did not affect these results. The difference 455 
in M1/M4R binding density results between males and females could also be partly attributed 456 
to sexual dimorphism in the severity of cognitive symptoms. We have previously shown that 457 
female poly I:C offspring have impaired recognition memory but intact working memory [17], 458 
which differed to the male poly I:C offspring who showed impairments in both cognitive 459 
measures [7]. There is also clinical evidence that male patients can exhibit greater cognitive 460 
impairment than females [49]. Literature suggests that muscarinic dysfunction, especially 461 
M1/M4R signaling, in schizophrenia patients strongly contributes to psychotic and cognitive 462 
symptoms [reviewed in 19]. Indeed, CBD treated the cognitive impairment exhibited by poly 463 
I:C male offspring [7] and restored cholinergic and M1/M4R deficits to control-like levels the 464 
PFC and HPC, ie regions of the brain relevant to cognition, in the same cohort of rats. These 465 
findings suggest that impairments in the muscarinic system are partly responsible for the 466 
cognitive deficits observed in the poly I:C male offspring and suggest that normalization of the 467 
M1/M4R binding density by CBD may have contributed to the improvement in cognition in 468 
these rats.  469 
 470 
M1/M4R binding density and AChE protein levels did not differ between female treatment 471 
groups and we observed a positive correlation between these markers in the HPC of female 472 
offspring. Furthermore, both markers were positively correlated with working performance in 473 
the T maze test, in which female treatment groups did not differ in performance [17] 474 
Conversely, in male offspring that showed alterations in muscarinic neurotransmission, 475 
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hippocampal M1/M4R binding density and AChE protein levels did not correlate with each 476 
other, or with T maze performance. Taken together, these findings could suggest that tight 477 
regulation of M1/M4R expression and ACh metabolism in the HPC is important for functional 478 
working memory. In other studies, decreased ChAT levels and M1R G protein-coupling were 479 
reported in the PFC of Alzheimer’s disease patients with severe cognitive impairment, with 480 
M1R levels correlating to the rate of cognitive decline [50]. Decreased muscarinic receptor G 481 
protein-coupled signalling in the PFC and HPC correlated to reduced spatial memory in aged 482 
rats [51] and decreased ChAT was correlated to age-related learning and memory deficits in 483 
mice [52]. Spatial working memory tasks that involve the HPC appear dependent on adequate 484 
cholinergic neurotransmission, particularly M1Rs that are expressed on excitatory pyramidal 485 
neurons [53]; therefore, hippocampal M1R downregulation may explain, in-part, the working 486 
memory deficits that we observed in male offspring. 487 
 488 
Down-regulated M1/M4R binding density in the poly I:C model could represent reduced 489 
cholinergic neurotransmission or a compensatory decrease in receptor density due to hyper-490 
cholinergic tone. However, while the mechanism underlying the CBD-induced alterations to 491 
muscarinic receptor density is unclear, one study recently reported that systemic administration 492 
of CBD to mice dose-dependently increased ACh levels in the forebrain within hours [24]. 493 
Indeed, we found that levels of the ACh synthesising enzyme, ChAT, were reduced in the HPC 494 
of poly I:C offspring, whereas CBD treatment resulted in control-like ChAT levels. On the 495 
other hand, the degrading enzyme, AChE, was unaltered in the HPC or PFC of any of the 496 
treatment groups. Therefore, the downregulated M1/M4R binding density in the poly I:C model 497 
is likely to have represented reduced cholinergic tone (ACh and M1/M4R signalling), whereas 498 
CBD alters muscarinic receptor density by restoring normal levels of ACh synthesis, not 499 
preventing degradation. To that effect, we observed a positive correlation between ChAT and 500 
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percentage of correct entries in the T Maze in male offspring, but no significant correlation 501 
between M1/M4R or AChE levels and cognitive performance in males. We also observed a 502 
significant positive correlation between ChAT and AChE protein levels in the PFC of both 503 
male and female offspring, suggesting that acetylcholine synthesis and metabolism is tightly 504 
regulated in this brain region. Our finding that CBD did not reduce AChE protein expression 505 
suggests that this molecule may not play a major role in CBD-induced cognitive performance; 506 
however, AChE enzymatic activity may be worth examining in future studies. The CB1R 507 
agonist Δ9-THC is a competitive inhibitor of AChE, in-vitro [54], but Δ9-THC effects on 508 
cognition can be either deleterious or beneficial. On the other hand, CBD may have a different 509 
mechanism of action as it did not alter AChE in the present study and was previously identified 510 
as a CB1R negative allosteric modulator, ie binds to an allosteric site on the receptor to reduce 511 
its activity, while traditional agonists/antagonists bind to the orthosteric site [55, 56]. 512 
Interestingly, cholinergic neurons projecting from the septum to the HPC release ACh, which 513 
increases production of post-synaptic endocannabinoids (via the M1R [57]) that regulate 514 
hippocampal excitation by controlling major inhibitory and excitatory neurotransmitters, 515 
GABA and glutamate, respectively [58]. Hippocampal excitation then affects signalling to 516 
higher brain regions, including the PFC, and is thought to contribute to the psychotic and 517 
cognitive symptoms of schizophrenia [59, 60]. Indeed, we previously reported imbalances in 518 
the level of glutamatergic NMDAR binding density in the PFC of female poly I:C offspring, 519 
while CBD treatment restored levels to that of the controls [17]. Taken together, CBD may 520 
alter signalling in the HPC and PFC through interactions with the cholinergic muscarinic, 521 
glutamatergic, GABAergic and endogenous cannabinoid systems to influence cognitive 522 




Given that CBD can improve cognitive function in a range of disease states that manifest 525 
impairment [9], its pro-cognitive effects may be attributed to a number of mechanisms. For 526 
example, one study showed that CBD is a dopamine D2 receptor (D2R) partial agonist, similar 527 
to the antipsychotic drug, aripiprazole [61]. Differing to risperidone and olanzapine, which 528 
have been associated with impaired cognition in some schizophrenia patients [62], aripiprazole 529 
improves cognition, including processing speed, attention and memory [63]. D2R activation 530 
has also been shown to increase hippocampal ACh levels in rats [64]. Therefore, the D2R 531 
partial agonist activity of CBD may be a contributing mechanism in its pro-cognitive effects 532 
via cholinergic signalling in the poly I:C model. CBD is also anti-inflammatory, 533 
neuroprotective and can stimulate neurogenesis [reviewed in 9, 10]. In a mouse model of 534 
cerebral malaria, CBD improved cognitive performance that was associated with increased 535 
neurogenic markers, such as brain-derived neurotrophic factor (BDNF), and reduced pro-536 
inflammatory cytokines, such as tumour necrosis factor (TNF)-α, in the HPC and PFC [65]. 537 
Therefore, future studies may consider investigating the role of these markers in the 538 
mechanisms underlying the pro-cognitive effects of CBD in the poly I:C model. In addition, 539 
while this study focussed on brain regions relevant to cognitive function, the mechanisms 540 
underlying the improvements in social interaction in the poly I:C model of schizophrenia 541 
following CBD treatment remain unknown [7] and further investigations focussing on regions 542 
involved in social functioning, particularly glutamatergic and GABAergic signalling in the 543 
amygdala [66], are required. 544 
 545 
Our study and others [67], have shown that CBD is psychoactive (i.e. alters brain signalling 546 
and changes behaviour), and is a promising novel therapeutic for a range of illnesses [9, 10]. 547 
However, the result that CBD treatment decreases M1/M4R binding density in the HPC and 548 
PFC of male control offspring in the present study has implications about its use in non-549 
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pathological states, particularly during adolescence/early adulthood which is a critical 550 
neurodevelopmental period. Further clinical studies are required to extrapolate these findings 551 
in humans. 552 
 553 
5. Conclusion: This study has revealed reductions in M1/M4R binding density and ChAT 554 
protein expression in the HPC and PFC of cognitively impaired male poly I:C offspring. The 555 
cholinergic deficits were treated using CBD. Further studies are required to confirm whether 556 
alterations to cholinergic neurotransmission are a cause or effect of cognitive deficits in the 557 
poly I:C model, as our data indicate a potential correlation between these observations. For 558 
example, pre-treating poly I:C offspring with a cholinergic/ChAT protein upregulator, such as 559 
donepezil [68], could provide useful data towards answering this question. Overall, our study 560 
revealed for the first time that muscarinic signalling in regions of the rat brain implicated in 561 
cognitive function is altered by CBD treatment. 562 
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